Screening, Characterization and Evaluation of Mangiferin Polymorphs

doi:10.1007/s13659-020-00247-z

Natural Products and Bioprospecting ›› 2020, Vol. 10 ›› Issue (4): 187-200.DOI: 10.1007/s13659-020-00247-z

• ORIGINAL ARTICLES • Previous Articles Next Articles

Screening, Characterization and Evaluation of Mangiferin Polymorphs

Shiying Yang¹, Qi Zhou¹, Baoxi Zhang¹, Li Zhang¹, Dezhi Yang¹, Haiguang Yang², Guanhua Du², Yang Lu¹

1 Beijing Key Laboratory of Polymorphic Drugs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
2 Beijing Key Laboratory of Drug Targets and Screening Research, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

Received:2020-04-14 Revised:2020-05-21 Online:2020-08-19 Published:2020-08-24
Contact: Guanhua Du, Yang Lu
Supported by:
The authors thank the financial support from Key National Research and Development Programmes (Grant No.2016YFC1000905), the Drug Innovation Major Project (Grant No. 2018ZX09711001-001-013), the National Natural Science Foundation of China (Grant No. 81703473), the Drug Innovation Major Project (Grant No. 2018ZX09711001-010, 2017ZX09101001003), and CAMS Innovation Found for Medical Sciences (Grant No. 2016-I2M-1-007).

Screening, Characterization and Evaluation of Mangiferin Polymorphs

Shiying Yang¹, Qi Zhou¹, Baoxi Zhang¹, Li Zhang¹, Dezhi Yang¹, Haiguang Yang², Guanhua Du², Yang Lu¹

1 Beijing Key Laboratory of Polymorphic Drugs, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China;
2 Beijing Key Laboratory of Drug Targets and Screening Research, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

通讯作者: Guanhua Du, Yang Lu
基金资助:
The authors thank the financial support from Key National Research and Development Programmes (Grant No.2016YFC1000905), the Drug Innovation Major Project (Grant No. 2018ZX09711001-001-013), the National Natural Science Foundation of China (Grant No. 81703473), the Drug Innovation Major Project (Grant No. 2018ZX09711001-010, 2017ZX09101001003), and CAMS Innovation Found for Medical Sciences (Grant No. 2016-I2M-1-007).

Abstract

Abstract: Mangiferin is a compound with many pharmacological activities and exists in many natural products. Anhydrous and hydrate of mangiferin have been reported separately in two literatures, but the polymorphism of this compound has not been realized until this paper. In this study, polymorph screening of mangiferin has been carried out and five forms have been obtained including three new forms never reported. Several solid state characterization methods, such as powder X-ray diffraction, differential scanning calorimetry and thermogravimetry, are used to identify and characterize all of mangiferin forms. The comparison of the crystallographic data and hirshfeld surface analysis were first reported for mangiferin anhydrous and hydrate. Furthermore, the studies on stability, transformation and solubility have been undertaken, the results prompt that form V can be used as the dominant polymorph for the development of innovative pharmaceuticals.

Key words: Mangiferin, Polymorph screening, Characterize, Stability, Solubility

摘要： Mangiferin is a compound with many pharmacological activities and exists in many natural products. Anhydrous and hydrate of mangiferin have been reported separately in two literatures, but the polymorphism of this compound has not been realized until this paper. In this study, polymorph screening of mangiferin has been carried out and five forms have been obtained including three new forms never reported. Several solid state characterization methods, such as powder X-ray diffraction, differential scanning calorimetry and thermogravimetry, are used to identify and characterize all of mangiferin forms. The comparison of the crystallographic data and hirshfeld surface analysis were first reported for mangiferin anhydrous and hydrate. Furthermore, the studies on stability, transformation and solubility have been undertaken, the results prompt that form V can be used as the dominant polymorph for the development of innovative pharmaceuticals.

关键词: Mangiferin, Polymorph screening, Characterize, Stability, Solubility

Shiying Yang, Qi Zhou, Baoxi Zhang, Li Zhang, Dezhi Yang, Haiguang Yang, Guanhua Du, Yang Lu. Screening, Characterization and Evaluation of Mangiferin Polymorphs[J]. Natural Products and Bioprospecting, 2020, 10(4): 187-200.

Shiying Yang, Qi Zhou, Baoxi Zhang, Li Zhang, Dezhi Yang, Haiguang Yang, Guanhua Du, Yang Lu. Screening, Characterization and Evaluation of Mangiferin Polymorphs[J]. 应用天然产物, 2020, 10(4): 187-200.

References

1. P. Jyotshna, K. Khare, Shanker. BioFactors 42, 504-514 (2016)
2. T. Ehianeta, S. Laval, B. Yu, BioFactors 42, 445-458 (2016)
3. S. Iseda, Bull. Chem. Soc. Jpn. 30, 629-633 (1957)
4. P.E. Nott, J.C. Roberts, Phytochemistry 6, 1597-1599 (1967)
5. V. Peres, T.J. Nagem, F.F. De Oliveira, Phytochemistry 55, 683-710 (2000)
6. I. Carpenter, H.D. Locksley, F. Scheinmann, Phytochemistry 8, 2013-2025 (1969)
7. D. Chen, R. Chen, R. Wang, J. Li, K. Xie, C. Bian, L. Sun, X. Zhang, J. Liu, L. Yang, F. Ye, X. Yu, J. Dai, Angew. Chem. 54, 12678-12682 (2015)
8. T. Sato, A. Kawamoto, A. Tamura, Y. Tatsumi, T. Fujii, Chem. Pharm. Bull. 40, 721-724 (1992)
9. P.M. Pauletti, I. Castro-Gamboa, D.H. Siqueira, I. Silva, M.C. Young, D.M. Tomazela, M.N. Eberlin, V. da SilvaBolzani, J. Nat. Prod. 66, 1384-1387 (2003)
10. Z.Q. Wei, L. Yan, J.G. Deng, J. Deng, Chin. J. Chin. Mater. Med. 13, 1798-1802 (2011)
11. H.W. Guo, J.G. Deng, C.X. Yun, G.H. Hou, J. Du, Chin. J. Exp. Trad. Med. Formul. 18, 187-190 (2012)
12. M.S. Zheng, Z.Y. Lu, Acta Pharm. Sin. 10, 85-90 (1989)
13. S.A.J. Nunez, M. Daglia, L. Rastrelli, BioFactors 42, 475-491 (2016)
14. H. Li, J. Huang, B. Yang, T. Xiang, X. Yin, W. Peng, W. Cheng, J. Wan, F. Luo, H. Li, G. Ren, Toxicol. Appl. Pharmacol. 272, 180-190 (2013)
15. G.C. Jagetia, M.S. Baliga, Phytomedicine 12, 209-215 (2005)
16. Z.P. Wang, J.G. Deng, Z.Y. Tan, Lishizhen Med. Mater. Med. Res. 20, 2167-2168 (2009)
17. X. Zhu, Y.Q. Cheng, L. Du, Y. Li, F. Zhang, H. Guo, Y.W. Liu, X.X. Yin, Phytother. Res. 29, 295-302 (2015)
18. P.S. Sellammuthu, P. Arulselvan, B.P. Muniappan, S. Fakurazi, M. Kandasamy, J. Med. Food. 16, 719-727 (2013)
19. Y. Niu, W. Lu, L. Gao, H. Lin, X. Liu, L. Li, Pharm Biol. 50, 1177-1182 (2012)
20. H.G. Yang, Q.M. Zhou, H.G. Wang, X. Cheng, X.Y. Zhao, Y. Lu, L.H. Fang, G.H. Du, Chin. Pharm. Bull. 34, 1356-1362 (2018)
21. J.Q. Wei, Z.M. Zheng, Y. Pan, J. Guangxi Med. Univ. 25, 732-733 (2008)
22. S. Muruganandan, J. Lal, P.K. Gupta, Toxicology 215, 57-68 (2005)
23. K.R. Morris, N. Rodriguez-Hornedo, in:J. Swarbrick, J. Boylan, Encyclopedia of Pharmaceutical Technology, vol. 7 (Marcel Dekker Inc., New York, 1993), pp. 393-440
24. Y. Lu, G.H. Du, Polymorphic Drugs (People's Medical Publishing House, Beijing, 2009), pp. 1-9
25. V. Lopez-Mejías, A.J. Matzger, Cryst. Growth Des. 15, 3955-3962 (2015)
26. H.G. Brittain, Polymorphism in Pharmaceutical Solids (Marcel Dekker, New York, 1999), pp. 279-330
27. S.Y. Yang, G.H. Du, Y. Lu, J. Mol. Struct. 1095, 79-86 (2015)
28. M. Li, H.J. Wang, D.M. Wu, Nat. Prod. Res. Dev. 19, 374-378 (2007)
29. J.W. da Cruz, L.R. de Moraes, M.H. dos Santos, G.A. da Silva, M.R.P.L. Brigagão, J. Ellena, A.C. Doriguetto, Helv. Chim. Acta 91, 144-154 (2008)
30. M.A. Spackman, D. Jayatilaka, Cryst. Eng. Comm. 11, 19-32 (2009)
31. N.B. Gong, Y. Wang, B.X. Zhang, D.Z. Yang, G.H. Du, Y. Lu, Steroids 143, 18-24 (2019)
32. G.P. Stahly, Cryst. Grow. Des. 7, 1007-1026 (2007)

[1]	Zhipeng Wang, Qi Li, Qi An, Lixiang Gong, Shiying Yang, Baoxi Zhang, Bin Su, Dezhi Yang, Li Zhang, Yang Lu, Guanhua Du. Optimized solubility and bioavailability of genistein based on cocrystal engineering [J]. Natural Products and Bioprospecting, 2023, 13(4): 30-30.
[2]	Ningbo Gong, Hongmei Yu, Ying Wang, Cheng Xing, Kun Hu, Guanhua Du, Yang Lu. Crystal Structures, Stability, and Solubility Evaluation of a 2: 1 Diosgenin-Piperazine Cocrystal [J]. Natural Products and Bioprospecting, 2020, 10(4): 261-267.

Screening, Characterization and Evaluation of Mangiferin Polymorphs

Screening, Characterization and Evaluation of Mangiferin Polymorphs

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 2

Recommended Articles

Metrics

Comments